J.P. Morgan 44th Annual Healthcare Conference failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelli ...

SciSparc Ltd. (NASDAQ:SPRC) announced a definitive agreement to acquire a portfolio of medical endoscopy patents on Tuesday. • SciSparc shares are retreating from recent levels. What’s behind SPRC decline?The company provided details of its planned purchase of intellectual property.SciSparc said it would acquire a treasury of patents, trademarks and related rights tied to endoscopic systems and medical cameras.The intellectual property included assets linked to the MUSE endoscopic system designed for minima ...

Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no ...

Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415<td style="vertical-align: middle; text-ali ...

Medtronic has outlined both its current market position and ambitious future at the ongoing J.P. Morgan Healthcare Conference. During its presentation, Medtronic stated that several of the key markets it targets, including pulsed-field ablation (PFA) and renal denervation, have the potential to become multi-billion-dollar opportunities in the near future. Following years of investing, Medtronic is now ready to focus on growth. According to GlobalData’s US Healthcare Facility Invoicing Database, Medtronic ...

Summary of Zimmer Biomet FY Conference Call (January 13, 2026) Company Overview - **Company**: Zimmer Biomet (NYSE: ZBH) - **Industry**: Medical Technology (MedTech), specifically Orthopedics Key Points and Arguments Company Transformation and Growth - Zimmer Biomet has undergone significant transformation over the past five years, shifting from a product-focused to a solutions-oriented approach, with an emphasis on cultural change [4][5] - The company reported a Compound Annual Growth Rate (CAGR) of 6.5% over the last five years, with revenue growth of 10% in 2021, 6.5% in 2022, and 7.5% in 2023 [5][6] - Adjusted earnings per share (EPS) for 2023 was $9.50, with a leverage of 200 basis points [5] U.S. Market Focus - The U.S. market accounts for 63% of Zimmer Biomet's revenue and over 51% of its debt [7] - The company aims to accelerate the transformation of its sales model in the U.S. to improve accountability and ownership [6][7] - A significant change in the U.S. sales model is planned, with a focus on specialization and direct sales [22] Innovation and Product Development - The company has shifted from launching eight products in 2018 to over 50 new products in the last three years, with 22 launched in 2025 alone [10][11] - Key innovations include the introduction of the first iodine-coated device aimed at preventing infections, set to launch in Japan in late 2025 [17][18] - The company is focusing on customer-centric innovation, addressing issues such as infection, efficiency, and patient outcomes [20][31] Market Dynamics - The orthopedic market is projected to grow at a rate of 4% to 4.25%, with Zimmer Biomet's performance tied to maintaining growth above this benchmark [13] - The company has seen consistent price positivity over the last seven quarters, indicating a favorable pricing environment [42] Financial Outlook - The company expects free cash flow to grow by 70% over the next five to six years, with 2026 anticipated to see free cash flow growth outpacing EPS growth [27][56] - Guidance for 2026 is tempered, aligning with the level of transformation expected, with projected organic growth of 3.5% to 4% [35][36] Strategic Investments - Zimmer Biomet has made three acquisitions in the past 14 months, including OrthoGrid and Paragon 28, to enhance its product offerings and market position [27][28] - The company plans to significantly increase its workforce dedicated to robotic solutions and ASCs (Ambulatory Surgery Centers) [24][25] Challenges and Execution - The company acknowledges the need for improved execution to ensure steady growth, addressing past inconsistencies in quarterly performance [20][21] - The transition to a specialized sales force is expected to create short-term disruptions but aims for mid- to long-term growth acceleration [46] Future Vision - By 2030, Zimmer Biomet aims to innovate beyond traditional implants, focusing on cartilage repair and leveraging data for predictive analytics in orthopedic care [32][33][34] Additional Important Insights - The company has improved employee engagement, making it to Forbes' World's Best Employers list for the first time [11] - Zimmer Biomet is committed to building a best-in-class company, focusing on operational excellence, innovation, and a strong company culture [30][34] This summary encapsulates the key points discussed during the conference call, highlighting Zimmer Biomet's strategic direction, market dynamics, and future aspirations in the orthopedic industry.

DALLAS, TX and CAMPBELL, CA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (“Strive”) announces Semler Scientific, Inc. (“Semler Scientific”) stockholders voted to approve being acquired by Strive. As part of the all-stock transaction, Strive will acquire Semler Scientific’s 5,048.1 Bitcoin. Strive also announces the purchase of 123 additional Bitcoin for its corporate treasury at an average price of $91,561 per Bitcoin, for a total purchase price of $11,264,000, inclusive of fees and expenses, bringing St ...

Core Viewpoint - West Pharmaceutical Services (WST) shares have shown a modest gain of 0.4% recently, closing at $272.91, with analysts suggesting a potential upside of 26.4% based on a mean price target of $345 [1][4]. Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets, with a standard deviation of $28.55, indicating variability among analysts [2]. - The lowest estimate is $285.00, suggesting a 4.4% increase, while the highest estimate is $390.00, indicating a potential surge of 42.9% [2]. - A low standard deviation signifies a strong consensus among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Optimism - Analysts are increasingly optimistic about WST's earnings, as indicated by upward revisions in earnings estimates, which historically correlate with stock price movements [11]. - Over the past 30 days, one estimate has increased, leading to a 0.3% rise in the Zacks Consensus Estimate for the current year [12]. - WST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of the stock's exact gains, it does provide a useful indication of the expected price movement direction [14].

Core Insights - Waters Corporation is acquiring Becton Dickinson's Biosciences and Diagnostic Solutions business to enhance its growth profile and expand its exposure to biologics, diagnostics, and regulated laboratory workflows [1] - The acquisition is expected to drive above-market growth and margin expansion over the coming years, as detailed at the JP Morgan Healthcare Conference [2] Financial Overview - BD's biosciences and diagnostic solutions unit is valued at approximately $3.3 billion, with an annual growth rate of roughly 5% from 2019 to 2024, and about 80% of its revenue is recurring [3] - Waters anticipates around $200 million in cost synergies within three years post-acquisition, with potential to exceed $300 million based on historical integrations [5] Strategic Rationale - The acquisition aligns with Waters' strategy to shift towards faster-growing and more defensible end markets, complementing its core strengths in analytical science [4] - The integration of BD's infrastructure is expected to enhance Waters' diagnostics strategy and expand its reach in therapeutic drug monitoring and clinical applications [4] Synergy Opportunities - Revenue synergies are projected from commercial execution, expansion into higher-growth adjacencies, and cross-selling, with high-growth adjacencies expected to generate about $150 million in incremental revenue by year five [6]

Core Viewpoint - Conavi Medical Corp. has successfully closed an equity offering, raising approximately $12 million to support the commercialization of its Novasight Hybrid system and other corporate purposes [1][2][4]. Group 1: Offering Details - The equity offering generated gross proceeds of approximately $12 million, with subscribers purchasing 26,666,670 common shares at a price of $0.45 per share [1][3]. - The proceeds will be utilized for obtaining US FDA 510(k) clearance for the Novasight Hybrid system and initiating a targeted market release in the United States, along with working capital and general corporate purposes [2][4]. Group 2: Company Background - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid system being the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) [7]. - The first-generation Novasight Hybrid system has already received 510(k) regulatory clearance in the U.S., Canada, China, and Japan [7]. Group 3: Agent and Compensation - Bloom Burton Securities Inc. acted as the sole agent for the offering, receiving a total cash commission of approximately $701,479.49 and 1,558,843 compensation options, each allowing the purchase of one common share at $0.45 until January 13, 2028 [3][6].